Compare Entegris Inc (ENTG) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Gilead Sciences, Inc. — how do they compare? Entegris Inc trades at $165.79 (market cap $24.78B), while Gilead Sciences, Inc. trades at $151.17 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 7.4× Entegris Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.23%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Gilead Sciences, Inc. for 111 Days on average.
| ENTG | GILD | |
|---|---|---|
Market Cap | $24.78B | $182.40B |
Volume | 2,648,320 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $184.00 | $155.80 |
52-Week Low | $68.80 | $116.74 |
Typical Hold Time | 41 Days | 111 Days |
Enterprise Value | $27.99B | $205.46B |
Dividend Yield | 0.25% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Entegris (ENTG) trades at $165.79, down 0.32% on the day, with strong technical momentum as the stock approaches resistance at $166. The company demonstrates solid fundamentals with Q2 2026 EPS of $0.93 beating expectations by 13%, driven by AI-related semiconductor demand. Revenue remains stable at $3.2B with improving net margins of 9.18%. Recent news highlights institutional accumulation and patent defense successes.
Outlook remains positive with 70% analyst buy ratings and $182.43 consensus target suggesting 10% upside. Key catalysts include Q3 earnings on October 29 and Investor Day on November 9. Risks include elevated valuation multiples (P/E 81.1) and semiconductor cycle sensitivity. The stock offers growth exposure to advanced semiconductor materials with institutional confidence.
Gilead Sciences (GILD) trades at $147.10, showing modest daily gains of 0.17% with strong technical support at $145. The company demonstrates robust fundamentals with Q2 2026 earnings beating expectations despite a net loss, while maintaining a high gross margin of 79.59%. Recent developments include expanded HIV prevention drug access across Latin America through a PAHO partnership, positioning the company for growth in key therapeutic areas.
GILD presents a mixed outlook with strong analyst support (65.5% buy ratings) and a $151.57 price target offering 3% upside, but faces headwinds from negative net income margins and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, though investors should monitor the company's ability to translate top-line strength into sustainable profitability amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
